Factors associated with respiratory tract viral infection identified by reverse-transcription PCR in lung transplant recipients
| Visits with upper (NPS) or lower (BAL) respiratory tract viral searches (n=903) | Visits with lower (BAL) respiratory tract viral searches (n=276)* | |||
|---|---|---|---|---|
| Negative | Positive | Negative | Positive | |
| N=729 | N=174 (19.3%) | N=242 | N=34 (12.3%) | |
| Time since transplantation | ||||
| <3 months, n (%) | 72 | 6 (7.7) | 61 | 1 (1.6) |
| 3 months to 1 year, n (%) | 120 | 24 (16.7) | 82 | 6 (6.8) |
| 1–3 years, n (%) | 126 | 38 (23.2) | 48 | 11 (18.6) |
| >3 years, n (%) | 411 | 106 (20.1) | 51 | 16 (23.9) |
| p=0.296† | p=0.001† | |||
| Tacrolimus level, μg/L, median (IQR) | n=397, 8.7 (3.2) | n=111, 9.9 (4.4) | n=139, 8.9 (3.8) | n=21, 10.7 (3.1) |
| Log-transformed tacrolimus level | 2.18 (0.36) | 2.27 (0.32) | 2.21 (0.36) | 2.32 (0.28) |
| p=0.015† | p=0.092† | |||
| Treatment for acute rejection during the preceding 3 months, n (%) | 65 | 14 (17.7) | 64 | 9 (12.3) |
| p=0.753† | p=0.998† | |||
| Study phase | ||||
| Screening period visits, n (%) | 487 | 83 (14.6) | 49 | 4 (7.6) |
| Routine visits, n (%) | 105 | 19 (15.3) | 113 | 7 (5.8) |
| Emergency visits, n (%) | 137 | 72 (34.5) | 80 | 23 (22.3) |
| p<0.001 | p<0.001 | |||
*Visits with BAL (n=276) are a subset of the total visits (n=903).
†p Value based on mixed logistic or linear models allowing for repeated measures within the preceding 3 months.
BAL, bronchoalveolar lavage; NPS, nasopharyngeal specimens.